Investor Celgene Corp /de/
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Celgene Corp /de/ . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2020-02-10 13G/A BGNE / BeiGene, Ltd. - Depositary Receipt (Common Stock) 32,746,416 32,746,416
2020-02-10 13G STRO / Sutro Biopharma, Inc. 1,726,197
2019-05-30 13G IDYA / IDEAYA Biosciences, Inc. 1,633,253
2019-01-22 13D/A XLRN / Acceleron Pharma Inc 6,157,458 6,863,664
2018-03-05 13D/A JUNO / Juno Therapeutics, Inc. 11,109,160 99,227,867
2018-02-22 13D/A JUNO / Juno Therapeutics, Inc. 11,109,160 11,109,160
2018-02-21 13D/A JUNO / Juno Therapeutics, Inc. 11,109,160 11,109,160
2018-02-14 13D/A JUNO / Juno Therapeutics, Inc. 11,109,160 11,109,160
2018-02-08 13D/A CRSP / CRISPR Therapeutics AG 3,306,819 2,800,772
2018-02-02 13D/A 11,109,160
2018-02-02 13D/A JUNO / Juno Therapeutics, Inc. 11,109,160 11,109,160
2018-01-22 13D/A JUNO / Juno Therapeutics, Inc. 11,109,160
2017-12-26 13D/A CRSP / CRISPR Therapeutics AG 3,722,534 3,306,819
2017-12-08 13G/A ATRA / Atara Biotherapeutics, Inc. 1,154,540
2017-12-06 13D/A CRSP / CRISPR Therapeutics AG 4,834,980 3,722,534
2017-09-25 13D/A XLRN / Acceleron Pharma Inc 5,411,866 6,157,458
2017-09-01 13G BGNE / BeiGene, Ltd. - Depositary Receipt (Common Stock) 32,746,416
2017-06-27 13D/A ALQA / Alliqua, Inc. 8,321,471 9,025,194
2017-04-13 13D/A ALQA / Alliqua, Inc. 8,025,194 8,321,471
2017-03-29 13D/A ALQA / Alliqua, Inc. 8,025,194 8,025,194
2017-03-16 13D/A ALQA / Alliqua, Inc. 8,025,194 8,025,194
2017-03-01 13D/A ALQA / Alliqua, Inc. 8,025,194
2016-10-31 13D CRSP / CRISPR Therapeutics AG 4,834,980
2016-08-24 13G OMED / OptMed Inc 2,970,588 2,970,588
2016-08-23 13G OMED / OptMed Inc 2,970,588
2016-01-11 13D/A XLRN / Acceleron Pharma Inc 4,025,194 5,411,866
2015-05-04 13D/A XLRN / Acceleron Pharma Inc 4,025,194
2015-02-13 13G/A TNGNQ / Tengion, Inc.
2015-02-13 13G ATRA / Atara Biotherapeutics, Inc. 1,256,235
2015-02-11 13G/A OMED / OptMed Inc 1,470,588
2014-05-06 13D/A XLRN / Acceleron Pharma Inc 4,611,866
2014-04-15 13D/A XLRN / Acceleron Pharma Inc 3,222,997
2014-04-02 13D/A XLRN / Acceleron Pharma Inc 3,511,866
2014-03-07 13D/A ADYX / Adynxx, Inc. 2,508,711
2014-02-12 13G/A TNGNQ / Tengion, Inc.
2014-01-30 13D/A XLRN / Acceleron Pharma Inc 3,511,866
2013-12-16 13G OMED / OptMed Inc 1,470,588
2013-11-27 13D ALQA / Alliqua, Inc. 2,508,711
2013-10-03 13D XLRN / Acceleron Pharma Inc 3,211,866
2012-10-09 13G TNGNQ / Tengion, Inc.